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Abstract
Background: Major depression is a common psychiatric disorder, frequently taking a chronic course. Despite
provision of evidence-based treatments, including antidepressant medication and psychological treatments like
cognitive behavioral therapy or interpersonal therapy, a substantial amount of patients do not recover.
Mindfulness-Based Cognitive Therapy (MBCT) has been found to be effective in reducing relapse in recurrent
depression, as well as lowering symptom levels in acute depression. The effectiveness of MBCT for chronic,
treatment-resistant depression has only be studied in a few pilot trials. A large randomized controlled trial is
necessary to examine the effectiveness of MBCT in reducing depressive symptoms in chronic, treatment-resistant
depression.
Methods/Design: A randomized-controlled trial is conducted to compare MBCT with treatment-as-usual (TAU).
Patients with chronic, treatment-resistant depression who have received antidepressant medication and cognitive
behavioral therapy or interpersonal therapy are included. Assessments take place at baseline and post intervention/
TAU-period. The primary outcome are depressive symptoms. Secondary outcomes are: remission rates, quality of life,
rumination, mindfulness skills and self-compassion. Patients in the TAU condition are offered to participate in the MBCT
after the post TAU-period assessment. From all completers of the MBCT (MBCT condition and patients participating
after the TAU-period), follow-up assessments are taken at three and six months after the completion of the MBCT.
Discussion: This trial will result in valuable information about the effectiveness of MBCT in chronic, treatment-resistant
depressed patients who previously received antidepressant medication and psychological treatment.
Trial registration: trialregister.nl NTR4843, registered 14th October 2014.
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Background
Major depression is one of the most common psychiatric
disorders. It has a large impact on individual’s wellbeing
and leads to high societal costs [1, 2]. The duration of a
depressive episode is highly variable. Whereas the majority
of people in the general population with a major depres-
sive episode recovers within several months, approxi-
mately 20 % of all depressed patients develop a chronic
course of depression [2, 3]. The latter is associated with
higher suicidality [4], increased comorbidity with other
psychiatric disorders, and impaired physical and psycho-
social functioning [5]. According to DSM-IV criteria, a de-
pressive episode is defined as chronic if the depressive
episode persists for at least two years [6]. However, results
of a large prospective epidemiological study on the preva-
lence of major depression in the Dutch population show,
that -even if treated in mental health care- the rate of re-
covery decreases after a few months. After one year, recov-
ery rates virtually stagnate, meaning that if no recovery
has taken place within 12 months the probability to de-
velop a chronic course of depression- as defined in the
DSM-IV- increases substantially [3].
Not only a chronic course of symptoms but also sev-
eral unsuccessful therapeutic interventions can be indi-
cative of a severe depressive episode. Patients who do
not respond to treatment are often described as ‘treat-
ment-resistant’. However, up till now, an unified and
clear definition of ‘treatment-resistant depression’ is
lacking. Definitions range from one single unsuccessful
attempt at antidepressant medication (ADM) to several
pharmacological interventions combined with electro-
convulsive therapy [7, 8]. In most clinical studies, a de-
pressive episode is regarded as treatment-resistant when
successive treatment with two antidepressants has not
led to a significant improvement of depressive symp-
toms. Interestingly, this definition does not take re-
sponse to psychological treatment into account, while
cognitive behavior therapy (CBT) or interpersonal ther-
apy (IPT) are part of international treatment guidelines
for recurrent and chronic depression [9]. Importantly,
research has shown that even when psychological and
pharmacological treatment options are combined, a sub-
stantial amount of patients fails to respond [10, 11]. This
means that there is a dire need of new treatment options
for chronic, treatment resistant depression.
In recent years, mindfulness based interventions have
been developed as a treatment focused on distress
caused by long-lasting somatic and psychological disor-
ders [12]. Mindfulness is defined as non-judgmental
awareness of the present moment [13] and was intro-
duced by Kabat-Zinn [14] as a treatment option for pa-
tients with chronic somatic conditions. Segal, Williams
and Teasdale [15] adapted the program for patients with
recurrent depression, naming it ‘Mindfulness Based
Cognitive Therapy’ (MBCT). MBCT is a group interven-
tion, consisting of eight weekly 2.5 h sessions and a si-
lent day of 6 h. It involves meditation exercises as well
as cognitive behavioral techniques. MBCT is designed to
address processes that are associated with the onset,
maintenance and recurrence of depression, such as mal-
adaptive automatic cognitive and behavioral patterns in
reaction to negative emotions or thoughts. In first in-
stance participants are taught to allow and acknowledge
negative emotions and thoughts as they are, without
having judgments about them or reacting to them. In this
way, they start recognizing their own maladaptive auto-
matic patterns. By creating a greater awareness of habitual
behavioral and cognitive patterns (e.g. avoidance or ru-
mination) participants learn to deliberately disengage from
them. Another important part of MBCT is to develop self-
compassion. MBCT differs from CBT in the sense that
the focus of cognitive therapy is more on the content of
thoughts, while MBCT focuses on the process of thinking.
In chronic depression, maladaptive automatic cognitive
and behavioral patterns often have become habitual.
Patients often experienced several episodes of depression
and an early onset of the disorder. To learn to react in a
different way to these maladaptive automatic cognitive
and behavioral patterns and to develop a non-judgmental
awareness of depressive symptoms might be especially
useful for this population. Therefore MBCT might be
effective in lowering depressive symptoms in chronic,
treatment resistant depression.
A recent meta-analysis [16] shows that MBCT is ef-
fective in preventing relapse in patients with recurrent
depression. Additionally, there is evidence, that MBCT
not only decreases chance of relapse of depression, but
that it lowers levels of residual or current depressive
symptoms. The first studies investigating the effect of
MBCT on residual symptoms in remitted depressed pa-
tients found significant improvements of depressive
symptoms [17, 18]. More recently, a meta-analysis was
conducted on the effects of MBCT in patients currently
meeting diagnostic criteria for a major depressive dis-
order [19]. The authors concluded that MBCT reduces
depressive symptoms in currently depressed patients and
might be as effective as CBT. One of the studies [20] in-
cluded in the meta-analysis specifically investigated pos-
sible differences of the effectiveness of MBCT between
remitted but still symptomatic and currently depressed
patients. The results indicate that MBCT was effective
for both remitted and currently depressed patients.
First results indicate that MBCT might also be a promis-
ing treatment option for chronic depression. Kenny and
Williams [21] reported a decrease in depressive symptoms
in a sample of currently depressed patients who experi-
enced symptoms for one year or longer, preceded by three
or more previous episodes. In line with that, Eisendrath et
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al. [22] found a significant decrease in depressive symptoms
after MBCT in currently depressed patients who previously
received at least two different antidepressants before start-
ing the MBCT training. In addition to these non-
randomized studies, two randomized-controlled pilot trials
demonstrated a significant reduction of depressive symp-
toms in chronically depressed patients. Barnhofer et al. [23]
found that after following MBCT less participants met full
criteria for a major depressive episode compared to a con-
trol group. Another study [24] investigated the effectiveness
of person-based cognitive therapy, a therapy combining
mindfulness techniques and cognitive therapy, in chronic
depression and found significant improvement of depres-
sive symptoms and mindfulness skills in the therapy group
compared to the control group. Importantly, all of these
studies report a good acceptance of the MBCT training
procedures by chronically depressed patients.
In sum, there is preliminary evidence that MBCT might
be effective in reducing depressive symptoms in chronic,
treatment-resistant patients. However well-powered ran-
domized controlled trials are necessary to systematically
examine the effectiveness of MBCT compared to treatment
as usual in this severely affected patient group. With the
current ongoing trial we will hopefully contribute to the
knowledge about treatment options for patients with per-
sistent depressive symptoms. Taking into account the high
risk for chronic depression if symptoms persist for more
than one year [3] we will recruit patients experiencing a de-
pressive episode for 12 months or longer who underwent
previous pharmacological and psychological treatment.
Aims
The aim of the current study is to investigate the effect of
MBCT compared to treatment as usual (TAU) on depres-
sive symptoms in patients with a current depressive epi-
sode persisting for at least 12 months, who previously
received pharmacological treatment, as well as either CBT
or IPT. We hypothesize that patients who receive MBCT
in addition to TAU will report lower levels of depressive
symptoms, higher quality of life, and less rumination,
compared to TAU alone. In addition, we expect that
mindfulness skills and self-compassion will improve in the
MBCT condition. Possible effects of level of treatment-
resistance and experience of childhood trauma on treat-
ment effect will also be investigated.
Methods/Design
Design
This study is a multi-center open-labeled randomized
controlled trial with two groups: MBCT+ TAU vs. TAU.
The study has been approved by the Medical Ethics
Committee Arnhem-Nijmegen (nr. 2012/339) for all par-
ticipating sites. Before randomization, written informed
consent is obtained from all participants. Primary and
secondary outcome measures are assessed at baseline
and after MBCT + TAU (8–12 weeks) or after a TAU-
period (8–12 weeks). Participants allocated to the TAU
condition are offered participation in the MBCT after
completion of the TAU-period and first follow-up assess-
ment. Of all participants who completed the MBCT,
follow-up measures take place at three and six months
after the end of treatment. For an overview of the re-
cruitment and measurement points see Fig. 1.
Participants
The study population consist of outpatients with a current
depressive episode lasting for 12 months or longer who
previously received ADM, as well as either CBT or IPT.
Patients are recruited at a university medical center
(Radboudumc Centre for Mindfulness) and at different lo-
cations of a regional mental health institution (Pro
Persona) in The Netherlands. Patients can be referred by
health care professionals, or can contact the research team
themselves for participation. Patients receive an informa-
tion letter and are contacted by phone one week later by
the research team. Patients are informed that participation
in the study is completely voluntary and that they can
withdraw from the study at any time. Participants are free
to receive additional treatment or to change their (dose
of) pharmacological medication during the study period.
Inclusion criteria:
 Age ≥ 18
 A current diagnosis of major depressive disorder
according to DSM-IV criteria with a duration
of ≥12 months
 Moderate to high level of current depressive
symptoms (Inventory of Depressive
Symptomatology- Self Report, IDS-SR ≥ 21)
 At least one adequate trial of ADM during the current
episode (defined as: appropriate doses of antidepressant
medication for ≥ 4 weeks; or patient’s refusal to use
medication in contrast to advise by a psychiatrist)
 Previous psychological treatment during the current
episode (defined as: ≥ 10 sessions of CBT or IPT;
or < 10 sessions if discontinued because of patient’s
withdrawal)
Exclusion criteria:
 Current psychotic symptoms
 Bipolar disorder according to DSM-IV
 Current alcohol or drugs dependence according to
DSM-IV
 Recent electro convulsive therapy (<3 months)
 Current somatic disorder (partly) explaining
depressive symptoms
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 Physical-, language-, cognitive-, or intellectual
impairments which interfere with participation in
MBCT or assessments
 Previous MBCT training
Procedure
Assessment of eligibility, baseline measures and
randomization
All patients who indicated their interest in the study are
invited for a research interview. Written informed consent is
obtained during this first appointment. To assess eligibility
and to classify comorbid psychiatric disorders, participants
are interviewed by a research psychologist or psychiatrists in
training with the depression, anxiety, psychosis and addiction
modules of the Mini International Neuropsychiatric Inter-
view (MINI; [25]). In addition, the following disorder-related
characteristics are assessed: duration of current major de-
pressive episode, number of psychological treatment sessions
(i.e. CBT and/or IPT) during current major depressive epi-
sode, duration and doses of pharmacological treatments
during the current depressive episode, number of depres-
sive episodes during lifetime and age of onset. On the base
Fig. 1 Flowchart of the recruitment and measurement points
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of these details the research assistant fills out the Dutch
Measure for quantification of Treatment Resistant De-
pression (DM-TRD, [26] [27]). After completion of the
baseline questionnaires, a computer program is used to
randomly allocate patients to either MBCT +TAU or
TAU. A minimization strategy is used for severity of
symptoms (IDS-SR ≥21 and ≤31 vs. > 31 and ≤ 39 vs. > 39)
and duration of major depressive episode (1–2 years
vs. > 2 years). If the period between randomization and
start of the MBCT training exceeds four weeks in the
MBCT +TAU condition, a repeated baseline assessment
takes place.
Follow-up assessments
The first follow-up measure takes place after the
MBCT training or the TAU-period. The MINI depres-
sion module is administered face-to-face or by phone
and participants fill out the questionnaires either on-
line or on paper. Participants are asked about changes
in pharmacological or psychological treatment during
the study period. Also participants deciding to discon-
tinue MBCT are asked to participate in follow-up mea-
sures. In all MBCT completers (MBCT +TAU and
participants of the TAU group who followed the MBCT
after the TAU-period), the same follow-up measures are
administered at three and six months after end of treat-
ment. Due to logistic reasons it is not possible to keep as-
sessors blind. To assess the inter-rater reliability of the
MINI, all diagnostic interviews are audio taped and a ran-
domly selected sample will be reassessed by an independ-




The MBCT consists of eight weekly sessions of 2.5 h
in groups of 8–15 patients and one additional day of si-
lent practice between the 5th and 7th session. Partici-
pants are asked to do daily homework assignments.
MBCT combines mindfulness meditation techniques, as
sitting meditation and the body scan with elements of
cognitive therapy such as psycho education and the
identification of automatic negative thoughts. The
MBCT manual described by Segal, Williams and Teas-
dale [13] is used. Participants are enrolled in regular
MBCT trainings provided at the Radboudumc Centre
for Mindfulness and Pro Persona for (remitted) de-
pressed patients. This means that the training groups
not only consist of study participants but also of regular
patients with a wide range of depressive symptoms.
MBCT trainings are taught by experienced mindful-
ness trainers who completed a 2-year post-graduate
teacher training program at the Radboudumc Centre for
Mindfulness. With this, they all meet the training cri-
teria described in the MBCT good practice guidelines
(UK Mindfulness-Based Teacher Trainer Network,
2011). Two MBCT sessions of each trainer are video-
taped to verify adherence to the MBCT protocol. In
addition to MBCT the participants receive TAU.
TAU
TAU may consist of any treatment the participant or
current mental health care specialist sees as necessary.
Participants are encouraged to continue treatment they
followed prior to enrolling in the study. The number of





The primary outcome measure is the level of depressive
symptoms measured with the Inventory of Depressive
Symptomatology Self-Report (IDS-SR). The IDS-SR is a
30-item self report questionnaire and has good psycho-
metric properties [28]. The IDS-SR has previously been
used in research on MBCT in depression and has been
shown to be sensitive to change [17].
Secondary outcome measures
Remission rates
Remission from depression according to DSM-IV criteria
is assessed with the major depression module of the Mini
International Neuropsychiatric Interview (MINI; [25]).
Table 1 Overview of measures and corresponding measurement
time points
Measure Target concept Baseline FU1 FU2 FU3 FU4





● ● ● ● ●
WHOQOL-
BREF
Quality of life ● ● ● ● ●
RRS-EXT Rumination ● ● ● ● ●
FFMQ Mindfulness skills ● ● ● ● ●







CTQ Childhood trauma ●
FU1: 2 weeks post intervention (MBCT + TAU)/8-12 weeks post baseline (TAU),
FU2: 3 months post intervention (MBCT+ TAU)/2 weeks post intervention
(TAU), FU3: 6 months post intervention (MBCT + TAU)/3 months post
intervention(TAU), FU4: 6 months post intervention (TAU)
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Quality of life
Perceived quality of life is measured using the 26
-item World Health Organization Quality of Life scale
(WHOQOL-BREF; [29]). Psychometric properties were
tested in a sample of Dutch psychiatric outpatients
and are considered to be good [30].
Rumination
Rumination is measured with the extended version of
the Ruminative Response Scale (RRS-EXT [31, 32]. The
RRS-EXT distinguishes between a more reflective way of
thinking (i.e. reflective pondering) and a more maladap-
tive way of thinking about symptoms (i.e. brooding) [33].
Mindfulness skills
Mindfulness skills are measured with the Five Facets
Mindfulness Questionnaire (FFMQ. [34]. The FFMQ
consists of 39 items which are divided in five subscales:
observing, describing, acting with awareness, non-
judging of inner experience and non-reactivity of inner
experience. The Dutch version of the FFMQ has good
psychometric properties [35, 36] and has previously been
used in research on mindfulness skills in bipolar dis-
order [37].
Self-compassion
Self-compassion is assessed with the Self Compassion
Scale (SCS; [38, 39]). The SCS is an 26-item self report
measure and consists of six components: self-kindness,
self-judgment, common humanity, isolation, mindful-
ness, and over-identification. The scale has good psycho-
metric properties and high scores on the SCS are related
to psychological well-being [39].
Possibly moderating variables
Treatment-resistance
The Dutch Measure for quantification of Treatment
Resistant Depression (DM-TRD; [26, 27]) is used to
investigate treatment-resistance of the current depres-
sive episode. With the DM-TRD several dimensions of
treatment-resistance are scored by the clinician (duration,
symptom severity, functional impairment, comorbid anx-
iety symptoms, prosocial stressors, treatment failures of
pharmacological and psychological treatment) which leads
to a total score ranging from 2–26.
Childhood trauma
To assess the experience of traumatic childhood events,
participants fill out the Childhood Trauma Question-
naire (CTQ-SF; [40]). This 28-item questionnaire mea-
sures traumatic experiences and maltreatment during
childhood. The CTQ-SF has previous been validated in a
Dutch clinical sample [41].
Data handling
All study-related information is stored in secure folders
with limited access. Paper-based data collection forms
only contain participant numbers to maintain participant
confidentiality and are stored in a locked cabinet in an
area with limited access. Electronic data files are pass-
word protected. The list linking participant number and
personal information is stored in a separated password
protected file. Paper-based data entry will be double
checked. Data will be stored for 15 years after the end of
inclusion. The study has low to negligibly risks therefore
no data monitoring committee is assigned. Only the first
author and principal investigators or persons assigned
by them will have access to the final data set. Authors of
the final trial report will have made substantial contribu-
tion to the design, conduction, interpretation and report-
ing of the trial. We will not use professional writers.
Study results will be presented via publications and pre-
sentations; study participants, funders and involved clini-
cians will receive a summary of the study results.
Statistical analyses
Power analysis and sample size
A power analysis was executed based on the findings
of van Aalderen et al. [20]. Van Aalderen and colleagues
[20] reported an effect size of 0.53 (Cohen’s d) in a sam-
ple of 69 currently depressed patients. Based on an alpha
of 0.05 and power of 80 %, estimating the correlation be-
tween baseline and first follow-up measurements to be
0.5 and intending to use an ANCOVA controlling for
baseline levels of depression, a needed sample size of 43
per condition was calculated. Expecting a drop-out of 8
patients, a total of 94 participants will be recruited.
Analyses plan
The MBCT +TAU and TAU conditions will be compared
on baseline sample characteristics to ensure that all pos-
sible meaningful characteristics were evenly distributed
across the conditions. To examine treatment outcome, we
will use both intention-to-treat and per-protocol samples.
Participants are considered completers of the MBCT if
they attend at least four sessions of MBCT. To examine
whether effects for participants experiencing a depressive
episode for one to two years and participants meeting cri-
teria for chronic depression according to the DSM-IV
(≥2 years) are different, the primary and secondary ana-
lyses will be repeated in these subgroups.
Primary analysis
The effect of condition (MBCT + TAU vs. TAU) on the
primary outcome measure (depressive symptoms) will be
examined using general linear models. Condition and
baseline score of depressive symptoms will be included
as independent variables, depressive symptoms at FU1
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as the dependent variable. Because MBCT is delivered in
mixed groups consisting of regular patients and a few
study participants and previous studies did not yield an
effect of therapy group [20], we will not incorporate a
random group effect.
Secondary analyses
Effects on quality of life, rumination, mindfulness skills,
and self-compassion will also be investigated using gen-
eral linear models with the same independent variable as
in the primary analysis. To investigate effects on remis-
sion rates a χ2 test will be performed. Moderating effects
of level of treatment-resistance and childhood trauma
will be investigated by including an interaction effect
(condition*moderator) in the models. Furthermore, ex-
ploratory analyses on rumination, mindfulness skills and
self-compassion as possible underlying mechanisms of
change will be conducted. Consolidation and moderation
of treatment effect will be investigated in the whole sam-
ple of MBCT completers (MBCT +TAU and TAU) using
end-of-treatment assessments and follow-up assessments
at three and six months after end of treatment.
Discussion
Despite the range of currently available treatments op-
tions such as antidepressant medication and cognitive
behavioral or interpersonal therapy, a substantial num-
ber of currently depressed patients do not recover [10].
Chronic, treatment-resistant depression is associated
with a high personal as well as societal burden [4, 5].
Additional treatment options are required, to further re-
duce depressive symptoms and to improve quality of life
in this population.
In previous pilot studies, MBCT appeared to be a prom-
ising treatment option for patients with chronic depres-
sion. Besides incorporating effective elements of cognitive
behavioral therapy, MBCT focuses on acknowledging
negative emotions and thoughts and disengaging from
maladaptive automatic cognitive and behavioral patterns
elicited by them. As chronic, treatment-resistant depres-
sion is characterized by perseverance of symptoms and a
long treatment history, maladaptive automatic thinking
patterns are likely to have become habitual. Therefore
MBCT might be a very valuable additional treatment for
this group. In the current study we will build upon the
previous pilot findings by studying the effect of MBCT on
depressive symptoms in a large chronic, treatment-
resistant sample in a randomized controlled trial.
Strauss and colleagues [19] argue that MBCT might
be as effective as cognitive behavioral therapy in redu-
cing depressive symptoms in currently depressed pa-
tients. The results of the current study will provide an
indication of the effectiveness of MBCT over and above
available pharmacological and psychological treatments
such as CBT and IPT, in patients who previously re-
ceived these types of psychological treatment.
In addition to the effects of MBCT on depressive
symptoms, we will investigate if MBCT leads to less ru-
mination and higher quality of life in this patient popu-
lation. Moreover, this trial will inform clinicians and
researchers if chronic, treatment-resistant depressed pa-
tients are able to learn mindfulness skills and to develop
more self-compassion by following a standard MBCT
training. This large trial will also give more detailed in-
formation about the acceptability and effect sizes of
MBCT in this target group.
The ecological validity of the study will be high, as
participants will be enrolled in standard Dutch MBCT
courses offered at mental health care institutions. If
the conclusion will be that MBCT is effective in
reducing depressive symptoms in chronic, treatment-
resistant depression, this study could make a signifi-
cant impact on treatment options for this severely
depressed target group.
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